



# 2011 Fall Symposium

November 5, 2011  
Airport Marriott Hotel  
Long Beach, CA

7:30 am	<b>Registration/Exhibits/Continental Breakfast</b>	1:15 pm	<b>Local Fascinating Cases*</b>
8:30 am	<b>Opening Remarks</b> <b>Bonnie V. Bock, M.D.</b> <i>President, IDAC</i>		<b>Objective:</b> At the completion of this activity, the participant will be better able to apply recommendations for diagnosis, screening, and treatment of unusual cases seen in clinical practice by IDAC members.
8:40 am	<b>The Bacteriology of Regressive Autism*</b> <b>Sydney M. Finegold, M.D.</b> <i>Emeritus Staff Physician, Infectious Diseases Section, VA Medical Center, West Los Angeles</i> <i>Emeritus Professor of Medicine and Microbiology, Immunology, and Molecular Genetics, UCLA School of Medicine, Los Angeles, CA</i>	2:15 pm	<b>What Has Infection Control Taught Us About Practical Isolation Practices?*</b> <b>Robert A. Weinstein, M.D.</b> <i>Chief Operating Officer, Ruth M. Rothstein CORE Center</i> <i>Chairman, Division of Infectious Diseases, Stroger Hospital</i> <i>Professor of Medicine, Rush University Medical Center, Chicago, IL</i>
	<b>Objective:</b> At the completion of this activity, the participant will be better able to: (1) inform the parent(s) of patients with regressive autism that progress is being made on understanding the causes of this disease and potential management; (2) learn that in regressive autism, intestinal bacteria play a role and that the bacteria involved may be selected out, or increase in numbers, as a result of exposure to certain antimicrobial agents such as cephalosporins and penicillins; and (3) learn of the availability of diagnostic tests.		<b>Objective:</b> At the completion of this activity, the participant will be better able to: (1) discuss the scientific literature and evidence for current isolation policies and practices and (2) implement infection control procedures to improve patient care.
9:40 am	<b>Morning Break / Industry Exhibits</b>	3:15 pm	<b>Reducing the Burden of Clostridium difficile Infection: From Initial Treatment to Recurrence Prevention***</b> <b>Charalabos Pothoulakis, M.D., D.Sci.</b> <i>Eli and Edythe Broad Professor of Medicine</i> <i>Director, Inflammatory Bowel Disease Center, Div. of Digestive Diseases, UCLA David Geffen School of Medicine, Los Angeles, CA</i>
10:00 am	<b>Current and Future Strategies for the Optimal Management of HIV/AIDS**</b> <b>Charles Hicks, M.D.</b> <i>Professor of Medicine, Duke University Medical Center, Durham, NC</i>		<b>Objective:</b> At the completion of this activity, the participant will be better able to: (1) discuss the pathophysiology of <i>Clostridium difficile</i> infection (CDI) as it relates to clinical disease; (2) analyze elements which contribute to the economic burden of CDI; (3) identify important risk factors for initial CDI and recurrence; and (4) apply therapeutic strategies for improved patient outcomes; and implement methods to prevent CDI in high-risk patients.
	<b>Objective:</b> At the completion of this activity, the participant will be better able to: (1) apply the concepts of treatment as prevention and test and treat to improve individual HIV patient and public health; (2) interpret and implement the newest HIV guidelines recommending earlier initiation of antiretroviral therapy for patients who are treatment-naïve, and those who have coinfection/comorbidities; (3) manage HIV coinfection with HBV and/or HCV according to contemporary guidelines for diagnosis and treatment; (4) analyze the deleterious effect of immune activation and premature aging in HIV on risk for complications, considering the newest recommendations and data for earlier therapy and preferred agents; and (5) select the optimal resistance and tropism testing to perform upon treatment failure, given the latest guidelines and testing options available.	4:15 pm	<b>Symposium Ends</b>
11:00 am	<b>Fungal Infections: 2011*</b> <b>Kieren A. Marr M.D.</b> <i>Professor of Medicine and Oncology</i> <i>Director, Transplant and Oncology ID, Johns Hopkins University School of Medicine, Baltimore, MD</i>	4:30 pm	<b>I.D. Fellow Mentoring Session</b> An informal round table discussion for fellows to interact with IDAC members, addressing questions about opportunities in private clinical practice.
	<b>Objective:</b> At the completion of this activity, the participant will be better able to: (1) discuss issues pertaining to antifungals and (2) apply recent changes in epidemiology and outcomes of fungal infections.	4:30 pm	<b>I.D. Pharmacist Break Out Session</b> An informal discussion of issues of particular interest to pharmacists with an interest in infectious diseases.
Noon	<b>Lunch/Industry Exhibits</b>		
12:30 pm	<b>IDAC Organizational Meeting</b>		

\* The Infectious Disease Association of California designates these educational activities for a maximum of 4.0 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.

\*\* The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The Johns Hopkins University School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AKH Inc is accredited by the American Academy of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. AKH Inc. designates this educational activity for 1.0 contact hour(s) for nurses and nurse practitioners. AKH Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. AKH Inc. approves this KNOWLEDGE-based activity for 1.0 contact hour (0.10 CEUs) UAN 0077-9999-11-018-L02-P. Attendees should only claim credit commensurate with the extent of their participation in the activity.

\*\*\* The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians. The Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number—809-9999-11-096-L01-P). The Postgraduate Institute for Medicine is approved by the California Board of Registered Nursing, Provider Number 13485 for 1.2 contact hours. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be mailed to you within 4 weeks.